Pharmaceutical kits comprising mesenchymal stem cells

• US 20060130852A1
• Filed: 09/08/2003
• Published: 06/22/2006
• Est. Priority Date: 09/07/2002
• Status: Active Grant

• Current Assignee: Recellerate Inc.
• Original Assignee: Quy Biosciences Limited
• Inventors: McGarrell, Kenneth Gregory, Smith, Roger Kenneth Whealands, Goodship, Allen Edward, Blunn, Gordon William
• Granted Patent: US 8,178,084 B2
• Time in Patent Office: Days
• US Class Current: 128/898
• CPC Class Codes: A61K 35/16 Blood plasma; Blood serum umbilical cord blood A61K35/51
• CPC Class Codes: A61K 35/19 Platelets; Megacaryocytes
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/32 Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
• CPC Class Codes: A61K 35/33 Fibroblasts
• CPC Class Codes: A61K 35/51 Umbilical cord; Umbilical cord blood; Umbilical stem cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/04 for non-specific disorders of the connective tissue

Abstract

A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom. The method is particularly suited to the regeneration of tendons in competitive mammals, such as the superficial digital flexor tendon of the horse.

Claims

1. A method of treating a natural soft skeletal tissue injury in a patient the method comprising administering to the patient a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom.

2. A method according to claim 1 wherein the injury is strain induced.

3. A method according to claim 1 wherein the composition of mesenchymal stem cells or tenocytes is administered at the site of tissue injury.

4. A method according to claim 1 wherein the soft skeletal tissue is a tendon or ligament.

5. A method according to claim 1 wherein the patient is a mammal.

6. A method according to claim 5 wherein the mammal is a human or a non-human mammal of economic importance.

7. A method according to claim 6 wherein the non-human mammal is selected from the group consisting of horses, dogs and camels.

8. A method according to claim 1 wherein the patient is a horse.

9. A method according to claim 1 wherein the patient is a horse or a camel and the soft skeletal tissue is selected from the group consisting of superficial digital flexor tendon (SDFT), suspensory ligament, deep digital flexor tendon, meniscus, cruciate ligament, and accessory ligament of the deep digital flexor tendon.

10. A method according to claim 1 wherein the patient is a dog and the soft skeletal tissue is selected from the group consisting of Achilles tendon, cruciate ligament, meniscus, flexor tendon and intervertebral disc.

11. A method according to claim 1 wherein the patient is a human and the soft skeletal tissue is selected from the group consisting of Achilles tendon, quadriceps tendon, rotator cuff, medial and lateral epicondylitis, cruciate ligament, meniscus and intervertebral disc.

12. A method according to claim 1 wherein the mesenchymal stem cells or tenocytes are allogenic.

13. A method according to claim 12 wherein the mesenchymal stem cells or tenocytes are autologous.

14. A method according to claim 13 wherein the mesenchymal stem cells are derived from the bone marrow of the patient.

15. A method according to claim 13 wherein the mesenchymal stem cells are derived from umbilical cord blood previously recovered from the patient.

16. A method according to claim 1 wherein the liquid suspension of mesenchymal stem cells or tenocytes is injected.

17. A method according to claim 1 wherein biological signals which encourage the mesenchymal stem cells to form tenocytes are also administered to the patient.

20. A method according to claim 1 wherein the site of injury is cleansed of damaged tissue and any early repair scar tissue starting to form at the site before administration of the composition of mesenchymal stem cells or tenocytes.

18. (canceled)

19. A kit of parts comprising (1) a composition of mesenchymal stem cells in liquid suspension enriched compared to the natural source of said cells, or tenocytes derived therefrom, (2) means for delivering the liquid suspension of stem cells to a site of natural soft skeletal tissue injury in a patient and (3) means for determining that the means for delivering locate to the site of injury.